Overview

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
0
Participant gender:
All
Summary
A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Seven and Eight Biopharmaceuticals Inc
Treatments:
Pembrolizumab
Criteria
Inclusion Criteria

1. Histologically or cytologically confirmed advanced or metastatic solid tumors that
have disease progression after treatment with all available therapies for metastatic
disease that are known to confer clinical benefit, or are intolerant to treatment, or
refuse standard treatment. Note: there is no limit to the number of prior treatment
regimens

2. Evidence of progressive disease (PD) within 3 months of signing the informed consent
form.

3. Have measurable disease

Exclusion Criteria:

1. Has disease that is suitable for local therapy administered with curative intent.

2. Prior exposure to TLR7 agonists, TLR8 agonists, TLR 7/8 dual agonists, and TLR9
agonists.

Other protocol defined inclusion/exclusion criteria could apply